AIMT insider filings
Aimmune Therapeutics, Inc. — 22 most recent insider filings (SEC Forms 3/4/5) from EDGAR, normalized by FilingPulse. Latest filing: 2020-10-15. Screen AIMT transaction legs live →
Insider transaction summary — last 90 days
No insider filings (Forms 3/4/5) for AIMT between 2026-08-23 and 2026-11-21. The table below lists the most recent filings on record.
Recent insider filings — Aimmune Therapeutics, Inc.
| Filed | Form | Insider | Reported transactions | Source |
|---|---|---|---|---|
| 2020-10-15 | 4 | Societe des Produits Nestle S.A. — 10% owner | Purchase (P): 43,435,583 @ $34.50 · Purchase (P): 10,681,704 @ $34.50 | EDGAR |
| 2020-10-14 | 4 | Oxtoby Andrew — Chief Commercial Officer | Code (U): 6,345 @ $34.50 · Disposition to issuer (D): 20,250 @ $34.50 · Disposition to issuer (D): 150,000 (derivative) @ $12.56 · Disposition to issuer (D): 67,500 (derivative) @ $10.69 | EDGAR |
| 2020-10-14 | 4 | Dallas Jayson Donald Alexander — President and CEO, Director | Code (U): 30,422 @ $34.50 · Disposition to issuer (D): 89,250 @ $34.50 · Disposition to issuer (D): 350,000 (derivative) @ $3.82 · Disposition to issuer (D): 210,000 (derivative) @ $10.78 · Disposition to issuer (D): 200,000 (derivative) @ $10.69 | EDGAR |
| 2020-10-14 | 4 | Behar Gregory — Director | Other (J): 10,192 @ $0 · Disposition to issuer (D): 7,840 @ $34.50 · Disposition to issuer (D): 39,510 (derivative) @ $9.60 · Disposition to issuer (D): 17,500 (derivative) @ $16.24 · Disposition to issuer (D): 7,500 (derivative) @ $1.71 · Disposition to issuer (D): 11,432 (derivative) @ $14.60 · +1 more | EDGAR |
| 2020-10-14 | 4 | Seltzer Stacey Denenberg — Director | Code (U): 10,221 @ $34.50 · Disposition to issuer (D): 7,840 @ $34.50 · Disposition to issuer (D): 52,421 (derivative) @ $28.21 · Disposition to issuer (D): 19,755 (derivative) @ $19.10 · Disposition to issuer (D): 17,500 (derivative) @ $16.24 · Disposition to issuer (D): 7,500 (derivative) @ $1.71 · +2 more | EDGAR |
| 2020-10-14 | 4 | HAUMANN BRETT K — Director | Code (U): 6,250 @ $34.50 · Disposition to issuer (D): 13,313 @ $34.50 · Disposition to issuer (D): 25,453 (derivative) @ $17.39 | EDGAR |
| 2020-10-14 | 4 | Sheehy Douglas T. — See Remarks | Code (U): 47,450 @ $34.50 · Disposition to issuer (D): 36,875 @ $34.50 · Disposition to issuer (D): 22,361 (derivative) @ $21.55 · Disposition to issuer (D): 67,500 (derivative) @ $14.87 · Disposition to issuer (D): 75,000 (derivative) @ $0.43 · Disposition to issuer (D): 75,000 (derivative) @ $10.78 · +1 more | EDGAR |
| 2020-10-14 | 4 | Iwicki Mark T — Director | Code (U): 39,567 @ $34.50 · Disposition to issuer (D): 7,840 @ $34.50 · Disposition to issuer (D): 52,421 (derivative) @ $31.48 · Disposition to issuer (D): 87,368 (derivative) @ $28.21 · Disposition to issuer (D): 19,755 (derivative) @ $19.10 · Disposition to issuer (D): 17,500 (derivative) @ $16.24 · +3 more | EDGAR |
| 2020-10-14 | 4 | ENRIGHT PATRICK G — Director | Code (U): 70,561 @ $34.50 · Code (U): 91,697 @ $34.50 · Disposition to issuer (D): 7,840 @ $34.50 · Disposition to issuer (D): 65,849 (derivative) @ $34.36 · Disposition to issuer (D): 52,421 (derivative) @ $28.21 · Disposition to issuer (D): 19,755 (derivative) @ $19.10 · +4 more | EDGAR |
| 2020-10-14 | 4 | MCDADE MARK — Director | Code (U): 26,852 @ $34.50 · Disposition to issuer (D): 7,840 @ $34.50 · Disposition to issuer (D): 104,842 (derivative) @ $31.48 · Disposition to issuer (D): 19,755 (derivative) @ $19.10 · Disposition to issuer (D): 17,500 (derivative) @ $16.24 · Disposition to issuer (D): 7,500 (derivative) @ $1.71 · +2 more | EDGAR |
| 2020-10-14 | 4 | ADELMAN DANIEL C MD — Chief Medical Officer | Code (U): 41,464 @ $34.50 · Disposition to issuer (D): 22,343 @ $34.50 · Disposition to issuer (D): 135,068 (derivative) @ $23.05 · Disposition to issuer (D): 70,000 (derivative) @ $14.87 · Disposition to issuer (D): 56,250 (derivative) @ $0.43 · Disposition to issuer (D): 71,250 (derivative) @ $10.78 · +1 more | EDGAR |
| 2020-10-14 | 4 | FALBERG KATHRYN E — Director | Code (U): 65,192 @ $34.50 · Code (U): 69,894 @ $34.50 · Disposition to issuer (D): 7,840 @ $34.50 · Disposition to issuer (D): 19,755 (derivative) @ $19.10 · Disposition to issuer (D): 17,500 (derivative) @ $16.24 · Disposition to issuer (D): 7,500 (derivative) @ $1.71 · +2 more | EDGAR |
| 2020-10-14 | 4 | BJERKHOLT ERIC — Chief Financial Officer | Code (U): 27,805 @ $34.50 · Disposition to issuer (D): 23,905 @ $34.50 · Disposition to issuer (D): 264,800 (derivative) @ $15.06 · Disposition to issuer (D): 56,250 (derivative) @ $0.43 · Disposition to issuer (D): 78,750 (derivative) @ $10.78 · Disposition to issuer (D): 56,250 (derivative) @ $10.69 | EDGAR |
| 2020-10-05 | 4 | Sheehy Douglas T. — See Remarks | Option exercise (M): 30,888 @ $12.95 · Option exercise (M): 30,888 (derivative) @ $0 | EDGAR |
| 2020-10-05 | 4 | ADELMAN DANIEL C MD — Chief Medical Officer | Option exercise (M): 34,932 @ $11.45 · Option exercise (M): 34,932 (derivative) @ $0 | EDGAR |
| 2020-10-05 | 4 | BJERKHOLT ERIC — Chief Financial Officer | Option exercise (M): 5,200 @ $19.44 · Option exercise (M): 5,200 (derivative) @ $0 | EDGAR |
| 2020-09-23 | 4 | ENRIGHT PATRICK G — Director | Other (J): 6,113,134 @ $0 · Other (J): 91,697 @ $0 | EDGAR |
| 2020-09-16 | 4 | Oxtoby Andrew — Chief Commercial Officer | Tax withholding (F): 840 @ $34.25 | EDGAR |
| 2020-09-16 | 4 | Dallas Jayson Donald Alexander — President and CEO, Director | Tax withholding (F): 1,642 @ $34.25 | EDGAR |
| 2020-09-16 | 4 | Sheehy Douglas T. — See Remarks | Tax withholding (F): 840 @ $34.25 | EDGAR |
| 2020-09-16 | 4 | ADELMAN DANIEL C MD — Chief Medical Officer | Tax withholding (F): 840 @ $34.25 | EDGAR |
| 2020-09-16 | 4 | BJERKHOLT ERIC — Chief Financial Officer | Tax withholding (F): 840 @ $34.25 | EDGAR |
Recent 8-K events — Aimmune Therapeutics, Inc.
Items classified from EDGAR index headers. Browse recent 8-K filings market-wide, by item code →
| Filed | Form | Items reported | Source |
|---|---|---|---|
| 2020-10-19 | 8-K | 1.02 — Termination of a Material Definitive Agreement 2.01 — Completion of Acquisition or Disposition of Assets 2.04 — Triggering Events That Accelerate or Increase a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement 3.01 — Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing 3.03 — Material Modification to Rights of Security Holders 5.01 — Changes in Control of Registrant 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 5.03 — Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year 9.01 — Financial Statements and Exhibits | EDGAR |
| 2020-08-31 | 8-K | 1.01 — Entry into a Material Definitive Agreement 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?ticker=AIMT returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new ones to you in seconds. Get a free API key → · API docs